Abstract

Background

Evidence suggests that circulating resistin levels are altered in colorectal cancer (CRC) and breast cancer (BC). Again, polymorphisms in resistin-encoding gene RETN have been evaluated in CRC and BC. However, there is a scarcity of data establishing the relationship of resistin and RETN polymorphisms (rs1862513 and rs3745367) with these cancers. This study aimed to analyze the relationship of resistin levels and RETN polymorphisms with CRC and BC in a combined meta-analytic approach.

Main body of the abstract

After a comprehensive online literature search, screening and eligibility check, 41 articles (31 with resistin level and 10 with RETN polymorphisms) were retrieved for meta-analyses. The mean difference (MD) of resistin was calculated and pooled to investigate the effect sizes with a 95% confidence interval (CI), and the connection of genetic polymorphisms was analyzed with an odds ratio (OR) and 95% CI. The analysis showed that resistin level is significantly higher in CRC (MD = 3.39) and BC (MD = 3.91) patients. Subgroup analysis in CRC showed significantly higher resistin in serum (MD = 4.61) and plasma (MD = 0.34), and in BC, a significantly elevated resistin level was reported in premenopausal (MD = 7.82) and postmenopausal (MD = 0.37) patients. Again, RETN rs1862513 showed a significantly strong association with CRC (codominant 1—OR 1.24, codominant 2—OR 1.31, dominant model—OR 1.25, and allele model—OR 1.16) and with BC (codominant 2—OR 1.51, codominant 3—OR 1.51, recessive model—OR 1.51, and allele model—OR 1.21). RETN rs3745367 did not show any association with these cancers.

Short conclusion

Overall, our analysis indicates that higher circulating resistin levels are associated with an elevated risk of CRC and premenopausal and postmenopausal BC. Besides, rs1862513 in RETN gene is significantly connected with both CRC and BC.

Details

Title
The first combined meta‐analytic approach for elucidating the relationship of circulating resistin levels and RETN gene polymorphisms with colorectal and breast cancer
Author
Aziz, Md. Abdul 1 ; Akter, Tahmina 1 ; Sarwar, Md. Shahid 1 ; Islam, Mohammad Safiqul 1   VIAFID ORCID Logo 

1  Noakhali Science and Technology University, Department of Pharmacy, Faculty of Science, Sonapur, Bangladesh (GRID:grid.449503.f) (ISNI:0000 0004 1798 7083); Noakhali Science and Technology University, Laboratory of Pharmacogenomics and Molecular Biology, Department of Pharmacy, Sonapur, Bangladesh (GRID:grid.449503.f) (ISNI:0000 0004 1798 7083) 
Pages
27
Publication year
2022
Publication date
Dec 2022
Publisher
Springer Nature B.V.
ISSN
11108630
e-ISSN
20902441
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s43042-022-00240-w
ProQuest document ID
2670525115
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.